Victory Capital Management
SGMT icon

Victory Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Victory Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-77,420
Closed -$265K – 2518
2024
Q2 		$265K Buy
77,420
+25,480
+49% +$117K ﹤0.01% 2130
2024
Q1 		$282K Sell
51,940
-4,630
-8% -$33.3K ﹤0.01% 2138
2023
Q4 		$307K Buy
56,570
+38,610
+215% +$182K ﹤0.01% 2120
2023
Q3 		$158K Buy
+17,960
New +$239K ﹤0.01% 2239

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Victory Capital Management's SGMT Position: Q3 2024 in Review

Victory Capital Management sold out of Sagimet Biosciences (SGMT) in Q3 2024, closing a stake of 77,420 shares — an estimated $265K sold.

Victory Capital Management first reported a position in SGMT in Q3 2023 and held it in 4 quarters. The position peaked at $307K in Q4 2023. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2024.

  • Victory Capital Management reported no remaining Sagimet Biosciences position as of Q3 2024 after selling out during the quarter.
  • Victory Capital Management sold 77,420 Sagimet Biosciences shares in Q3 2024, an estimated $265K.
  • Victory Capital Management first reported a position in Sagimet Biosciences in Q3 2023 and held it in 4 quarters.
  • Victory Capital Management's Sagimet Biosciences position peaked at $307K in Q4 2023.
  • 63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2024.

Based on Victory Capital Management's 13F filing for Q3 2024, filed 5 Nov 2024.